ENOV ENOVIS CORPORATION

ENOVIS™ Showcases Next Generation of Medical Technology at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting

ENOVIS™ Showcases Next Generation of Medical Technology at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting

Medtech Leader Highlights Power of Collaboration in Its Continued Success and Innovation

Wilmington, DE, March 03, 2023 (GLOBE NEWSWIRE) --   (NYSE: ENOV), an innovation-driven medical technology company, announced that it will feature its next generation of medical technology at the upcoming American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting March 7-11, 2023 in Las Vegas. Aligned with AAOS, Enovis will also introduce its ‘’ corporate brand campaign that emphasizes the company’s ongoing collaboration with healthcare professionals, customers, and their patients, and how these partnerships advance medtech.

“For more than 40 years, Enovis – formerly DJO® – has worked to make the impossible possible through our groundbreaking products, services and software. But we know this great work can’t be accomplished alone,” said Matt Trerotola, CEO of Enovis. “At AAOS and beyond, we are excited to highlight how these partnerships are shaping the next generation of medtech.”

“The ‘Better Is’ campaign represents the invaluable collaboration I’ve experienced with Enovis as we revolutionized shoulder arthroplasty together through the design, development, research, and continued refinement of the AltiVate Reverse® Shoulder System – ground-breaking medical technology that now has 10 years of proven clinical data showing no decline in patient outcomesi,” said Mark A. Frankle*, M.D., Florida Orthopedic Institute. “I look forward to continuing to collaborate with Enovis on research that will help our development of even more next-generation orthopedic solutions that aim to improve patient results.”

Enovis is planning to feature a number of its products from across multiple business units at this year’s AAOS Annual Meeting, including:

  • Enovis Surgical will spotlight its ™, which is redefining revision with just one additional instrument tray and stackable augments for the femur and tibia, and ® Anatomic Augmented Glenoid (AG) System, which maximizes treatment solutions and is the only system available with both pegged symmetric and half-wedge augments. Live demos of the next generation  Augmented Reality System will also be available showcasing real-time, hands-free surgical guidance that is both efficient and space conserving for knee and hip arthroplasty.
  • Enovis Bracing & Supports will showcase its industry-leading ® Proe and ™ Hip Brace as the company targets a quickly growing hip arthroscopy market segment.
  • Enovis Healthcare Solutions will exhibit its ® Outpatient Arthroplasty Risk Assessment software as a part of Enovis’ industry-leading Healthcare Solutions platform, MotionMD®.
  • Enovis Foot & Ankle will feature its ™ with disruptive NiTinNOL technology and recently approved ® Ankle Patient Specific Instrumentation (PSI).

Find Enovis™ at AAOS

Enovis™ will be exhibiting at booth #821 in the Venetian Convention & Expo Center at AAOS. The company’s events at the meeting include:

  • Educational event focused on upper extremities titled “Maximizing Your aTSA Glenoid Solutions” on March 7 at 7:00 pm PT. Registration is available .
  • Educational event titled “Education with the Experts: Dual Pivot TKA, Revisions and Advanced Technology” on March 9 at 6:00 pm PT. Registration for this event is available .
  • Educational event to hear Ariel Palanca*, M.D. present biomechanical data from Enovis researchers regarding advances in total ankle polyethylene longevity on March 8 at 11:40am. This presentation is part of the AAOS Foot and Ankle I Papers session occurring from 11:00am to 12:30pm PT in Room 2103.

*Drs. Frankle and Palanca are paid consultants of Enovis.


About Enovis

Enovis Corporation (NYSE: ENOV) is an innovation-driven, medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit .



i Cuff et al. Reverse shoulder arthroplasty for the treatment of rotator cuff deficiency: a concise follow-up, at a minimum of 10 years, of previous reports. Journal of Bone and Joint Surgery. 2017

Kelvi® is a registered trademark of HYPOTHERMIA DEVICES, INC. dba Kelvi



Katie Sweet, Communications
  

Annika Parrish, Health+Commerce
 
EN
03/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENOVIS CORPORATION

 PRESS RELEASE

Enovis to Participate in Upcoming Investor Conferences

Enovis to Participate in Upcoming Investor Conferences Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13th at 8:30 a.m. Eastern Time.Wells Fargo Healthcare Conference on Wednesday, September 3rd at 2:15 p.m. Eastern Time.Baird 2025 Global Healthcare Conference on Wednesday, September 10th at 3:10 p.m. Eastern Time. A link to the l...

 PRESS RELEASE

Enovis Announces Second Quarter 2025 Results

Enovis Announces Second Quarter 2025 Results Continued commercial momentum with second-quarter sales growth of 7% on a reported basisSecond-quarter Reconstructive sales grew 11% year-over-year on a reported basis  Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Second Quarter 2...

 PRESS RELEASE

Enovis to Host Second Quarter 2025 Results Conference Call on August 7...

Enovis to Host Second Quarter 2025 Results Conference Call on August 7th Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at . Conference C...

 PRESS RELEASE

Enovis to Participate in Upcoming Investor Conferences

Enovis to Participate in Upcoming Investor Conferences Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Goldman Sachs 46th Annual Global Healthcare Conference: Ben Berry, Chief Financial Officer, will participate in a fireside chat on Tuesday, June 10th at 2:00 p.m. Eastern Time.Citizens Medical Devices and Healthcare Services Forum: Ben Berry, Chief Financial Officer, will participate in investor meet...

 PRESS RELEASE

Enovis Announces First Quarter 2025 Results

Enovis Announces First Quarter 2025 Results Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch